Cleerly LABS vs vascuCAP
AI Verdict
Choose Cleerly LABS if…
Choose Cleerly LABS if your primary need is comprehensive, AI-powered analysis of coronary CT angiography for longitudinal tracking of atherosclerosis and stenosis progression. This tool is ideal for personalized heart disease management, allowing clinicians to monitor changes in plaque volume and type over time to guide ongoing treatment strategies.
View Cleerly LABS →Choose vascuCAP if…
Choose vascuCAP (now ElucidVivo/PlaqueIQ) if your focus is on detailed, histologically-validated quantification of specific plaque components to assess acute cardiovascular risk, particularly for stroke and heart attack. This tool is best suited for scenarios requiring precise characterization of vulnerable plaque features, such as lipid-rich necrotic core and intraplaque hemorrhage, to inform immediate treatment decisions.
View vascuCAP →When choosing between Cleerly LABS and vascuCAP (now ElucidVivo/PlaqueIQ), physicians should consider their primary focus in cardiovascular imaging analysis. Cleerly LABS excels in comprehensive coronary CT angiography (CCTA) analysis, providing detailed quantification and characterization of atherosclerosis and stenosis. Its strengths lie in tracking disease progression over time and offering personalized heart disease risk assessments, making it particularly useful for longitudinal management of coronary artery disease. The system also offers an ISCHEMIA module for ischemia detection, further enhancing its utility for coronary assessment.
In contrast, vascuCAP (ElucidVivo/PlaqueIQ) specializes in non-invasive CT angiography analysis with a strong emphasis on histologically-validated plaque quantification and characterization. It provides detailed insights into plaque composition, including lipid-rich necrotic core, calcification, and intraplaque hemorrhage, which can be crucial for assessing cardiovascular risk for stroke and heart attack. The key practical difference lies in their primary application: Cleerly LABS is geared towards comprehensive coronary disease management and progression tracking, while vascuCAP offers a deeper dive into the specific composition of plaque across various arterial vessels for risk stratification.
Therefore, a physician primarily focused on managing coronary artery disease, tracking its progression, and assessing ischemia would likely find Cleerly LABS more aligned with their needs. Conversely, a physician requiring detailed, histologically-validated plaque characterization for broader cardiovascular risk stratification, including stroke risk, would benefit more from vascuCAP (ElucidVivo/PlaqueIQ). Both tools are FDA-cleared and HIPAA compliant, offering cloud-based deployment with integration capabilities for existing clinical workflows.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly LABS | vascuCAP |
|---|---|---|
| Pricing | Per analysis | Contact for pricing |
| Deployment | Cloud-based (AWS), web-based application, with on-site Cleerly Proxy for data transfer. | Cloud and on-premise |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly LABSCleerly LABS is explicitly described as a 'web-based software' and 'web-based application,' suggesting a straightforward and accessible user experience. While vascuCAP also offers 3D visualization and integration, its deployment options include both cloud and on-premise, which might imply a more complex setup for some users compared to Cleerly's dedicated web platform.
Clinical Value
vascuCAPvascuCAP distinguishes itself with 'Histologically-validated plaque quantification and characterization' and the ability to quantify specific, high-risk plaque components like lipid-rich necrotic core and intraplaque hemorrhage. While Cleerly LABS offers comprehensive plaque assessment and ischemia detection, the explicit histological validation and detailed plaque component analysis of vascuCAP provide a deeper, more rigorously validated insight into cardiovascular risk.
Pricing & Value
Cleerly LABSCleerly LABS provides transparent pricing information, including a retail price and a current discounted rate per analysis, allowing potential users to clearly understand the cost. In contrast, vascuCAP's pricing is listed as 'contact for pricing,' which makes it difficult to assess its value proposition without further inquiry.
Enterprise Readiness
vascuCAPBoth tools are FDA-cleared, HIPAA compliant, and offer BAA, with robust integration capabilities for PACS/EMR. However, vascuCAP offers both 'Cloud and on-premise secure deployment options,' providing greater flexibility to accommodate diverse enterprise IT infrastructures and security requirements compared to Cleerly LABS' cloud-based deployment with an on-site proxy.
Innovation
vascuCAPBoth tools leverage AI for advanced CCTA analysis. vascuCAP stands out with its 'Histologically-validated plaque quantification and characterization' and the ability to precisely quantify specific, critical plaque components such as lipid-rich necrotic core and intraplaque hemorrhage. This level of detailed and validated characterization represents a significant innovative advancement in non-invasive cardiovascular diagnostics.
Support & Docs
Cleerly LABSWhile neither JSON provides explicit details on support and documentation, Cleerly's website highlights resources for clinicians, including educational materials and webinars, suggesting a proactive approach to user enablement. Elucid Bioimaging (vascuCAP) also provides product information and scientific publications, but the available information does not explicitly detail the same level of dedicated support offerings.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly LABS | vascuCAP |
|---|---|---|
| Tool Name | Cleerly LABS | vascuCAP (now ElucidVivo/PlaqueIQ) |
| Company | Cleerly | Elucid Bioimaging |
| Description | AI-powered, FDA-cleared web-based software for comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management. | FDA-cleared AI software for non-invasive CT angiography analysis, quantifying plaque composition and assessing cardiovascular risk to optimize treatment decisions. |
| Key Features | AI-powered CCTA image analysis, Comprehensive coronary plaque assessment (volume, type), Stenosis detection and quantification, Ischemia detection (with Cleerly ISCHEMIA module), 3D visualization of coronary arteries, Personalized heart disease risk assessment, Tracking disease progression over time, Integration with PACS, RIS, EHR via Cleerly Proxy | AI-enabled CT angiogram analysis, Histologically-validated plaque quantification and characterization, 3D visualization of arterial vessels and plaque, Risk stratification for stroke and heart attack, Support for personalized treatment decisions, Quantification of lipid-rich necrotic core, calcification, non-calcified matrix, intraplaque hemorrhage, DICOM integration and PACS/EMR interoperability, Cloud and on-premise secure deployment options |
| Specialties | Cardiology, Radiology | Cardiology, Radiology, Vascular Surgery |
Videos
Demos, reviews, and walkthroughs featuring Cleerly LABS and vascuCAP.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly LABS or vascuCAP
Backers
Who funded each tool's parent company.